<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-28625" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Risperidone</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>McNeil</surname>
            <given-names>Shawn E.</given-names>
          </name>
          <aff>LSU Health Sciences Center Shreveport</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gibbons</surname>
            <given-names>Jonathan R.</given-names>
          </name>
          <aff>Touro College of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cogburn</surname>
            <given-names>Mark</given-names>
          </name>
          <aff>Louisiana State University HSC</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shawn McNeil declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jonathan Gibbons declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mark Cogburn declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>16</day>
          <month>1</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-28625.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">The Food and Drug Administration (FDA)-approved indications for oral risperidone (tablets, oral solution, and M-TABs) include the treatment of schizophrenia (in adults and children aged 13 and older), bipolar I acute manic or mixed episodes as monotherapy (in adults and children aged 10 and older), bipolar I acute manic or mixed episodes adjunctive with lithium or valproate (in adults), and autism-associated irritability (in children aged 5 and older). Also, the long-acting risperidone injection has been approved for the use of schizophrenia and maintenance of bipolar disorder (as monotherapy or adjunctive to valproate or lithium) in adults. There are also many varied non-FDA-approved uses for risperidone. This activity outlines the indications, mechanism of action, administration methods, significant adverse events, contraindications, and monitoring of risperidone so providers can direct patient therapy in treating conditions for which it is indicated as part of the interprofessional team.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action for risperidone.</p></list-item><list-item><p>Summarize the indications for initiating therapy with risperidone.</p></list-item><list-item><p>Review the contraindications and adverse event profile for risperidone.</p></list-item><list-item><p>Explain the importance of improving care coordination among the interprofessional team to enhance care delivery for patients who can benefit from therapy with risperidone.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28625&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28625">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-28625.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Risperidone is an atypical antipsychotic medication, first approved for use in the United States by the Food and Drug Administration (FDA) in 1993. The FDA-approved indications for oral risperidone (tablets, oral solution, and meltable tablets) include the treatment of:</p>
        <list list-type="bullet">
          <list-item>
            <p>Schizophrenia (in adults and children 13 and older)</p>
          </list-item>
          <list-item>
            <p>Bipolar I acute manic or mixed episodes as monotherapy (in adults and children 10 and older)</p>
          </list-item>
          <list-item>
            <p>Bipolar I acute manic or mixed episodes adjunctive with lithium or valproate (in adults)</p>
          </list-item>
          <list-item>
            <p>Autism-associated irritability (in children aged 5 and older)</p>
          </list-item>
        </list>
        <p>The long-acting risperidone injection has&#x000a0;received FDA approval&#x000a0;in the treatment of schizophrenia and maintenance of bipolar disorder (as monotherapy or adjunctive to valproate or lithium) in adults. There are many varied non-FDA-approved uses for risperidone. It has been used to treat psychotic symptoms when they are present. It has also been used for borderline personality, delusional disorder, delirium, depression, brain injury, pedophilia, post-traumatic stress disorder, bipolar disorder, conduct disorder, Lesch-Nyhan, Tourette, trichotillomania, stuttering, movement disorders, and developmental disorders.<xref ref-type="bibr" rid="article-28625.r4">[1]</xref><xref ref-type="bibr" rid="article-28625.r5">[2]</xref> In addition to psychotic symptoms, risperidone&#x000a0;has utility in treating aggression and agitation in patients with dementia. Risperidone has also been used to augment antidepressant therapy in the treatment of non-psychotic unipolar depression. In addition to irritability associated with autism, risperidone has also been used for social impairment, stereotypical behaviors, cognitive problems, and hyperactivity in autism.<xref ref-type="bibr" rid="article-28625.r9">[3]</xref><xref ref-type="bibr" rid="article-28625.r10">[4]</xref></p>
      </sec>
      <sec id="article-28625.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>All antipsychotics have some degree of antagonism at D2 receptors. First-generation antipsychotics produce antipsychotic effects at 60% to 80% D2 occupancy. Second-generation antipsychotics like risperidone exhibit their therapeutic effects through some D2 blockade but more from the blockade of serotonin receptors like 5HT2A. Second-generation antipsychotics have loose binding to D2 receptors and can quickly dissociate from the receptor, potentially accounting for the lower likelihood of causing extrapyramidal symptoms.<xref ref-type="bibr" rid="article-28625.r12">[5]</xref></p>
        <p>Moreover,&#x000a0;second-generation antipsychotics have an agonism at the 5HT1A receptor. Serotonin and norepinephrine reuptake inhibition are potential mechanisms by which risperidone is postulated to produce antidepressant effects. The improvement of positive symptoms is thought to be accomplished through the blockade of D2 receptors, specifically in the mesolimbic pathway. The ability of antipsychotics to block D2 receptors in the prefrontal cortex and nucleus accumbens is important in improving certain psychiatric symptoms. Of note, risperidone does not cause anticholinergic effects, which may benefit patients in certain populations, including the elderly with dementia.</p>
      </sec>
      <sec id="article-28625.s4" sec-type="Administration">
        <title>Administration</title>
        <p>This medication may be administered in oral form (tablets, solution, or dissolvable) or as a&#x000a0;long-acting injection. Patients should not cut or chew the orally disintegrating tablet formulation. It is also available in injectable form.</p>
        <p>
<bold>Dosing Based on Indications Follows:</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Schizophrenia:</bold>
<list list-type="bullet"><list-item><p>For the first episode, age younger 65 years: 1 to 3 mg/day orally divided into&#x000a0;one or&#x000a0;two doses. Stat at 1 mg daily, then increase the dose by 0.5 mg daily every 6 to 7 days to target 2 mg daily. The maximum dose is 16 mg daily, but doses exceeding 4 mg&#x000a0;per day are rarely more effective.</p></list-item><list-item><p>Maintenance dosing, age younger 65 years:&#x000a0;1 to 4&#x000a0;mg/day orally divided into&#x000a0;one or&#x000a0;two doses. Stat at 1 to 2 mg daily, then increase the dose by 0.5 mg per day every&#x000a0;three to seven days to target&#x000a0;4 mg daily. The maximum dose is 16 mg daily, but doses exceeding 4 mg&#x000a0;per day are rarely more effective.</p></list-item><list-item><p>Age 65 and older:&#x000a0;1 to&#x000a0;4 mg/day orally divided into 1 or 2 doses. Stat at&#x000a0;0.25 to 0.5 mg daily, then increase the dose by 0.5 mg per day every 6 to 7 days to target 2 mg daily. The maximum dose is 16 mg daily, but doses exceeding 4 mg per day are rarely more effective.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Acute manic/mixed bipolar disorder:</bold>
<list list-type="bullet"><list-item><p>1 to&#x000a0;6 mg/day orally divided into 1 or 2 doses. Stat at&#x000a0;2 to 3 mg daily, then increase the dose by&#x000a0;1 mg per day&#x000a0;no more frequently than every 24 hours to target 2 mg daily. The maximum dose is 6 mg daily.</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Tourette syndrome</bold> (off-label):
<list list-type="bullet"><list-item><p>0.2 to 3 mg daily by mouth divided once or twice daily. The maximum dose is 6 mg daily.</p></list-item></list>
</p>
          </list-item>
        </list>
        <p><bold>Renal dosing</bold>: If CrCl is less than 30, start at 0.5 mg orally twice daily; maybe increase by up to 0.5 mg twice daily until 1.5 mg twice a day, after which dosing should not increase more frequently than weekly.</p>
        <p><bold>Hepatic dosing:</bold> For Child-Pugh Class C,&#x000a0;start at 0.5 mg orally twice daily; maybe increase by up to 0.5 mg twice daily until 1.5 mg twice a day, after which dosing should not increase more frequently than weekly.</p>
      </sec>
      <sec id="article-28625.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Weight changes, metabolic changes, and sedation are significant concerns with risperidone. Risperidone may produce extrapyramidal symptoms (EPS), including acute dystonia, akathisia, tardive dyskinesia (TD), and Parkinsonian features. Acute/early EPS can occur at the beginning of treatment or when the dose is adjusted. Late-onset EPS (tardive dyskinesia) typically results from chronic treatment. Akathisia is a feeling of restlessness and may manifest as the patient pacing. Acute dystonia includes muscle spasms that result in abnormal postures and typically affect the head and neck. Parkinsonian features include skeletal muscle rigidity (often described as "cogwheel rigidity"), tremor, shuffling gait, and bradykinesia. Movements of the limbs, torso, neck, and head (commonly involving the tongue and lips) characterize tardive dyskinesia. This may also appear as facial grimacing or oculogyric crisis. EPS is thought to be due to D2 blockade in the nigrostriatal pathway. Since acute EPS symptoms often improve&#x000a0;with the cessation of the medication, these side effects are a major cause of noncompliance with treatment. Although these side effects are thought to be reversible, the duration of Parkinsonian features after discontinuation of the medication can vary. Tardive dyskinesia, however, will likely persist after the medication is discontinued and may be permanent. In addition to discontinuation of the antipsychotic, pharmacologic treatments are available that may help with certain extrapyramidal symptoms.<xref ref-type="bibr" rid="article-28625.r17">[6]</xref><xref ref-type="bibr" rid="article-28625.r18">[7]</xref>&#x000a0;One potential adverse effect of risperidone is orthostatic hypotension.&#x000a0;</p>
        <p>The antagonism of D2 receptors in the tuberoinfundibular pathway is believed to precipitate a rise in prolactin levels. The resulting hyperprolactinemia can precipitate sexual dysfunction, which has a prevalence of 45% to 80% among males and 30% to 80% among females taking this medication. Further, elevated prolactin can contribute to decreased libido, impaired arousal, and difficulty attaining orgasm. Sexual side effects may also be precipitated by risperidone's action at adrenergic (alpha 1, alpha 2) and histamine (H2) receptors. Gynecomastia, galactorrhea, and priapism have been reported in men, while galactorrhea and amenorrhea have been reported in women. It is important to note that children may be more susceptible to certain susceptible to some side effects and require careful monitoring.<xref ref-type="bibr" rid="article-28625.r19">[8]</xref></p>
        <p>Serious side effects of antipsychotic medications (like risperidone) can include neuroleptic malignant syndrome (NMS). Although the pathogenesis of NMS is not clear, it is a life-threatening condition that can manifest with altered mental status, fever, "lead pipe" rigidity, and autonomic instability, including hypertension, tachypnea, and tachycardia. The use of risperidone has also been linked to a higher probability of cerebrovascular events in older patients with dementia, leading to an FDA warning about using this medication in the context of dementia-related psychosis. Studies have even shown an increase in all-cause mortality among the elderly with dementia who are on this medication.<xref ref-type="bibr" rid="article-28625.r20">[9]</xref></p>
      </sec>
      <sec id="article-28625.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Risperidone should not be given if a known allergy/hypersensitivity to risperidone or paliperidone (a metabolite of risperidone) is present. Hallucinogen persisting perception disorder or HPPD may be a relative contraindication for risperidone because some patients treated with risperidone for their HPPD reported that panic and visual symptoms intensified.</p>
      </sec>
      <sec id="article-28625.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Although there are no mandatory requirements for therapeutic drug monitoring with risperidone, monitoring plasma concentrations for this medication is strongly recommended by European guidelines because of data showing interdependent variability. Therapeutic monitoring can benefit from assessing compliance and identifying low drug concentrations that may be low, resulting in therapeutic failure. Also, monitoring the drug level can aid in evaluating potential drug interactions and side effects. Specific parameters should be monitored while the patient is on antipsychotics, especially in children who are more sensitive to adverse effects.&#x000a0;When using risperidone,&#x000a0;the clinician may derive patient benefit by monitoring serum prolactin level, hepatic functioning, metabolic functioning, thyroid functioning, weight/body mass index, height, waist circumference, blood pressure, fasting plasma glucose, insulin, fasting lipid profile, and QTc.<xref ref-type="bibr" rid="article-28625.r25">[10]</xref><xref ref-type="bibr" rid="article-28625.r26">[11]</xref></p>
      </sec>
      <sec id="article-28625.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>An interprofessional healthcare team, including the primary care provider, nurse practitioner, psychiatrist, or emergency department physician who prescribes risperidone, must follow the patient. Nurses and pharmacists also play a crucial role in patient monitoring and directing the administration of the drug. The drug has many adverse effects, of which the most important are weight gain, metabolic changes, and sedation. Unlike the older antipsychotics, tardive dyskinesia is less frequently seen with the newer atypical antipsychotics like risperidone.<xref ref-type="bibr" rid="article-28625.r29">[12]</xref><xref ref-type="bibr" rid="article-28625.r30">[13]</xref>&#x000a0;Nevertheless, the onus is on the healthcare&#x000a0;team to detect any movement disorder and manage it. Countless litigations have occurred chiefly due to the lack of proper management of the adverse effects of risperidone. The optimal means to achieving the best therapeutic&#x000a0;goal is interprofessional communication and collaboration.<xref ref-type="bibr" rid="article-28625.r31">[14]</xref>&#x000a0;[Level 5]</p>
        <p>Serious side effects of antipsychotic medications (like risperidone) can include NMS. Although the pathogenesis of NMS is not clear, it is a life-threatening condition that can manifest with altered mental status, fever, "lead pipe" rigidity, and autonomic instability, including hypertension, tachypnea, and tachycardia. The use of risperidone has also been linked to a higher probability of cerebrovascular events in older patients with dementia, leading to an FDA warning about the use of this medication in the context of dementia-related psychosis. Studies have even shown an increase in all-cause mortality among older patients with dementia who are on this medication.<xref ref-type="bibr" rid="article-28625.r32">[15]</xref><xref ref-type="bibr" rid="article-28625.r29">[12]</xref></p>
      </sec>
      <sec id="article-28625.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28625&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28625">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/28625/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=28625">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-28625.s10">
        <title>References</title>
        <ref id="article-28625.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Keepers</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Fochtmann</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Anzia</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Benjamin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lyness</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Mojtabai</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Servis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Walaszek</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Buckley</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lenzenweger</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Degenhardt</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>SH</given-names>
              </name>
              <collab>(Systematic Review)</collab>
            </person-group>
            <article-title>The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia.</article-title>
            <source>Am J Psychiatry</source>
            <year>2020</year>
            <month>Sep</month>
            <day>01</day>
            <volume>177</volume>
            <issue>9</issue>
            <fpage>868</fpage>
            <page-range>868-872</page-range>
            <pub-id pub-id-type="pmid">32867516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28625.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nestsiarovich</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gaudiot</surname>
                <given-names>CES</given-names>
              </name>
              <name>
                <surname>Baldessarini</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Vieta</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tohen</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Preventing new episodes of bipolar disorder in adults: Systematic review and meta-analysis of randomized controlled trials.</article-title>
            <source>Eur Neuropsychopharmacol</source>
            <year>2022</year>
            <month>Jan</month>
            <volume>54</volume>
            <fpage>75</fpage>
            <page-range>75-89</page-range>
            <pub-id pub-id-type="pmid">34489127</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28625.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Siafis</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>&#x000c7;&#x00131;ray</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Schneider-Thoma</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bighelli</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Krause</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rodolico</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ceraso</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Deste</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Huhn</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fraguas</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>San Jos&#x000e9; C&#x000e1;ceres</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mavridis</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Charman</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Murphy</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Parellada</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Arango</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Leucht</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological and dietary-supplement treatments for autism spectrum disorder: a systematic review and network meta-analysis.</article-title>
            <source>Mol Autism</source>
            <year>2022</year>
            <month>Mar</month>
            <day>04</day>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>10</fpage>
            <pub-id pub-id-type="pmid">35246237</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28625.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Boman</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>De Butte</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Neurobehavioral effects of chronic low-dose risperidone administration in juvenile male rats.</article-title>
            <source>Behav Brain Res</source>
            <year>2019</year>
            <month>May</month>
            <day>02</day>
            <volume>363</volume>
            <fpage>155</fpage>
            <page-range>155-160</page-range>
            <pub-id pub-id-type="pmid">30735760</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28625.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Putignano</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Clavenna</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Reale</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bonati</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The evidence-based choice for antipsychotics in children and adolescents should be guaranteed.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>2019</year>
            <month>Jun</month>
            <volume>75</volume>
            <issue>6</issue>
            <fpage>769</fpage>
            <page-range>769-776</page-range>
            <pub-id pub-id-type="pmid">30729258</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28625.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Farhat</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Behling</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Landeros-Weisenberger</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Levine</surname>
                <given-names>JLS</given-names>
              </name>
              <name>
                <surname>Macul Ferreira de Barros</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Bloch</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette's syndrome: a systematic review and network meta-analysis.</article-title>
            <source>Lancet Child Adolesc Health</source>
            <year>2023</year>
            <month>Feb</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>112</fpage>
            <page-range>112-126</page-range>
            <pub-id pub-id-type="pmid">36528030</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28625.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Momosaki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kido</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Matsumoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Taniguchi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Akiyama</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sawada</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ozasa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>The Effect of S-Adenosylmethionine Treatment on Neurobehavioral Phenotypes in Lesch-Nyhan Disease: A Case Report.</article-title>
            <source>Case Rep Neurol</source>
            <year>2019</year>
            <season>Sep-Dec</season>
            <volume>11</volume>
            <issue>3</issue>
            <fpage>256</fpage>
            <page-range>256-264</page-range>
            <pub-id pub-id-type="pmid">31607891</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28625.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krajewski</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Zirpel</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Saceda-Corralo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tha&#x000e7;i</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Szepietowski</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Exploring pharmacological treatment for trichotillomania: do we need better education?</article-title>
            <source>Int J Dermatol</source>
            <year>2024</year>
            <month>May</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">38797877</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28625.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feiner</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chase</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Melbourne</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Rosen</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>Risperidone effects on heterochromatin: the role of kinase signaling.</article-title>
            <source>Clin Exp Immunol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>196</volume>
            <issue>1</issue>
            <fpage>67</fpage>
            <page-range>67-75</page-range>
            <pub-id pub-id-type="pmid">30714144</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28625.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fallah</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Shaikh</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Neupane</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Rusiecki</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Beyene</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Atypical Antipsychotics for Irritability in Pediatric Autism: A Systematic Review and Network Meta-Analysis.</article-title>
            <source>J Child Adolesc Psychopharmacol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>29</volume>
            <issue>3</issue>
            <fpage>168</fpage>
            <page-range>168-180</page-range>
            <pub-id pub-id-type="pmid">30707602</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28625.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feng</surname>
                <given-names>XZ</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>ZY</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>YY</given-names>
              </name>
              <name>
                <surname>Mi</surname>
                <given-names>WF</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Bao</surname>
                <given-names>YP</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>SX</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness and safety of second-generation antipsychotics for psychiatric disorders apart from schizophrenia: A systematic review and meta-analysis.</article-title>
            <source>Psychiatry Res</source>
            <year>2024</year>
            <month>Feb</month>
            <volume>332</volume>
            <fpage>115637</fpage>
            <pub-id pub-id-type="pmid">38150810</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28625.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meltzer</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Gadaleta</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Contrasting Typical and Atypical Antipsychotic Drugs.</article-title>
            <source>Focus (Am Psychiatr Publ)</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-13</page-range>
            <pub-id pub-id-type="pmid">34483761</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28625.r13">
          <label>13</label>
          <element-citation publication-type="book">
            <chapter-title>Risperidone</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>5</day>
            <pub-id pub-id-type="pmid">31644213</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28625.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Larsen</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Damkier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pedersen</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Fenger-Gron</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mikkelsen</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Linde</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Knudsen</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Skaarup</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Videbech</surname>
                <given-names>P</given-names>
              </name>
              <collab>Danish Psychiatric Society</collab>
              <collab>Danish Society of Obstetrics and Gynecology</collab>
              <collab>Danish Paediatric Society</collab>
              <collab>Danish Society of Clinical Pharmacology</collab>
            </person-group>
            <article-title>Use of psychotropic drugs during pregnancy and breast-feeding.</article-title>
            <source>Acta Psychiatr Scand Suppl</source>
            <year>2015</year>
            <issue>445</issue>
            <fpage>1</fpage>
            <page-range>1-28</page-range>
            <pub-id pub-id-type="pmid">26344706</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28625.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <collab>ACOG Committee on Practice Bulletins--Obstetrics</collab>
            <article-title>ACOG Practice Bulletin: Clinical management guidelines for obstetrician-gynecologists number 92, April 2008 (replaces practice bulletin number 87, November 2007). Use of psychiatric medications during pregnancy and lactation.</article-title>
            <source>Obstet Gynecol</source>
            <year>2008</year>
            <month>Apr</month>
            <volume>111</volume>
            <issue>4</issue>
            <fpage>1001</fpage>
            <page-range>1001-20</page-range>
            <pub-id pub-id-type="pmid">18378767</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28625.r16">
          <label>16</label>
          <element-citation publication-type="book">
            <chapter-title>Risperidone</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2024</year>
            <month>10</month>
            <day>15</day>
            <pub-id pub-id-type="pmid">30000154</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28625.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stogios</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bowden</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tran</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Asgariroozbehani</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>McIntyre</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Remington</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Siskind</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Hahn</surname>
                <given-names>MK</given-names>
              </name>
            </person-group>
            <article-title>Metabolic adverse effects of off-label use of second-generation antipsychotics in the adult population: a systematic review and meta-analysis.</article-title>
            <source>Neuropsychopharmacology</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>47</volume>
            <issue>3</issue>
            <fpage>664</fpage>
            <page-range>664-672</page-range>
            <pub-id pub-id-type="pmid">34446830</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28625.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jiwanmall</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Gopalakrishnan</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kuruvilla</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Tardive laryngeal dystonia with risperidone - A case report.</article-title>
            <source>Indian J Psychiatry</source>
            <year>2021</year>
            <season>May-Jun</season>
            <volume>63</volume>
            <issue>3</issue>
            <fpage>306</fpage>
            <page-range>306-307</page-range>
            <pub-id pub-id-type="pmid">34211231</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28625.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trinchieri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Trinchieri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Perletti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Magri</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Stamatiou</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cai</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Montanari</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Trinchieri</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Erectile and Ejaculatory Dysfunction Associated with Use of Psychotropic Drugs: A Systematic Review.</article-title>
            <source>J Sex Med</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>18</volume>
            <issue>8</issue>
            <fpage>1354</fpage>
            <page-range>1354-1363</page-range>
            <pub-id pub-id-type="pmid">34247952</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28625.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Misawa</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Okumura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Takeuchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fujii</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Takeuchi</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Neuroleptic malignant syndrome associated with long-acting injectable versus oral second-generation antipsychotics: Analyses based on a spontaneous reporting system database in Japan.</article-title>
            <source>Schizophr Res</source>
            <year>2021</year>
            <month>May</month>
            <volume>231</volume>
            <fpage>42</fpage>
            <page-range>42-46</page-range>
            <pub-id pub-id-type="pmid">33752105</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28625.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ford</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Sallam</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Towler</surname>
                <given-names>HM</given-names>
              </name>
            </person-group>
            <article-title>Intraoperative floppy iris syndrome associated with risperidone intake.</article-title>
            <source>Eur J Ophthalmol</source>
            <year>2011</year>
            <season>Mar-Apr</season>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>210</fpage>
            <page-range>210-1</page-range>
            <pub-id pub-id-type="pmid">20853271</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28625.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Matsuo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sano</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ikeda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Fujihara</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tanito</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Intraoperative floppy-iris syndrome associated with use of antipsychotic drugs.</article-title>
            <source>Can J Ophthalmol</source>
            <year>2016</year>
            <month>Aug</month>
            <volume>51</volume>
            <issue>4</issue>
            <fpage>294</fpage>
            <page-range>294-296</page-range>
            <pub-id pub-id-type="pmid">27521670</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28625.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lauterbach</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Abdelhamid</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Annandale</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Posthallucinogen-like visual illusions (palinopsia) with risperidone in a patient without previous hallucinogen exposure: possible relation to serotonin 5HT2a receptor blockade.</article-title>
            <source>Pharmacopsychiatry</source>
            <year>2000</year>
            <month>Jan</month>
            <volume>33</volume>
            <issue>1</issue>
            <fpage>38</fpage>
            <page-range>38-41</page-range>
            <pub-id pub-id-type="pmid">10721882</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28625.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>YF</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>High-Dose Risperidone Induced Latent Syndrome of Inappropriate Antidiuretic Hormone Secretion With Seizure Presentation.</article-title>
            <source>Clin Neuropharmacol</source>
            <year>2015</year>
            <season>Jul-Aug</season>
            <volume>38</volume>
            <issue>4</issue>
            <fpage>154</fpage>
            <page-range>154-5</page-range>
            <pub-id pub-id-type="pmid">26166241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28625.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Panizzutti</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bortolasci</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Spolding</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kidnapillai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Connor</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Richardson</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Truong</surname>
                <given-names>TTT</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>ZSJ</given-names>
              </name>
              <name>
                <surname>Gray</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Dean</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>Berk</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Walder</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Biological Mechanism(s) Underpinning the Association between Antipsychotic Drugs and Weight Gain.</article-title>
            <source>J Clin Med</source>
            <year>2021</year>
            <month>Sep</month>
            <day>10</day>
            <volume>10</volume>
            <issue>18</issue>
            <pub-id pub-id-type="pmid">34575210</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28625.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Guber</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Cortes</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Duan</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Risk of Obesity Among Children Prescribed Atypical Antipsychotics for Six Months or More.</article-title>
            <source>J Child Adolesc Psychopharmacol</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>32</volume>
            <issue>1</issue>
            <fpage>52</fpage>
            <page-range>52-60</page-range>
            <pub-id pub-id-type="pmid">34283934</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28625.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chakrabarty</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Bennett</surname>
                <given-names>JI</given-names>
              </name>
              <name>
                <surname>Baloch</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Hawk</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Natof</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Increasing Abnormal Involuntary Movement Scale (AIMS) Screening for Tardive Dyskinesia in an Outpatient Psychiatry Clinic: A Resident-Led Outpatient Lean Six Sigma Initiative.</article-title>
            <source>Cureus</source>
            <year>2023</year>
            <month>May</month>
            <volume>15</volume>
            <issue>5</issue>
            <fpage>e39486</fpage>
            <pub-id pub-id-type="pmid">37378259</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28625.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kambayashi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Izumi-Nakaseko</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Takei</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sugiyama</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>&#x003b2;-Adrenoceptor blockade can augment the torsadogenic action of risperidone.</article-title>
            <source>J Pharmacol Sci</source>
            <year>2024</year>
            <month>Oct</month>
            <volume>156</volume>
            <issue>2</issue>
            <fpage>134</fpage>
            <page-range>134-141</page-range>
            <pub-id pub-id-type="pmid">39179332</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28625.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buhagiar</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jabbar</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Association of First- vs. Second-Generation Antipsychotics with Lipid Abnormalities in Individuals with Severe Mental Illness: A Systematic Review and Meta-Analysis.</article-title>
            <source>Clin Drug Investig</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>253</fpage>
            <page-range>253-273</page-range>
            <pub-id pub-id-type="pmid">30675684</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28625.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chen</surname>
                <given-names>TR</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>YC</given-names>
              </name>
            </person-group>
            <article-title>Risperidone-Associated Neuroleptic Malignant Syndrome in an Inpatient With Schizophrenia, With Successful Rechallenge and 3 Year Follow-Up.</article-title>
            <source>Front Psychiatry</source>
            <year>2018</year>
            <volume>9</volume>
            <fpage>718</fpage>
            <pub-id pub-id-type="pmid">30618887</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28625.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Comparative efficacy and safety of therapy for the behavioral and psychological symptoms of dementia: a systemic review and Bayesian network meta-analysis.</article-title>
            <source>J Neurol</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>266</volume>
            <issue>10</issue>
            <fpage>2363</fpage>
            <page-range>2363-2375</page-range>
            <pub-id pub-id-type="pmid">30666436</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28625.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pozzi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pisano</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Marano</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Carnovale</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bravaccio</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rafaniello</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Capuano</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rossi</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Rizzo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bernardini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nobile</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Molteni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Clementi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Biganzoli</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Radice</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Weight-Change Trajectories of Pediatric Outpatients Treated with Risperidone or Aripiprazole in a Naturalistic Setting.</article-title>
            <source>J Child Adolesc Psychopharmacol</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>29</volume>
            <issue>2</issue>
            <fpage>133</fpage>
            <page-range>133-140</page-range>
            <pub-id pub-id-type="pmid">30452281</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
